Federal Court finds invalidity allegations relating to patent for metformin formulations not justified

Smart & Biggar
Contact

Smart & BiggarOn March 8, 2019, Justice Fothergill granted Valeant Canada’s application for an order prohibiting the Minister of Health from issuing a notice of compliance to Generic Partners for its generic version of Valeant’s GLUMETZA, a metformin formulation: Valeant Canada v Generic Partners Canada2019 FC 253.

Generic Partners had alleged that Patent No. 2,290,624, for controlled release dosage forms of drugs such as metformin, was invalid for anticipation, obviousness, double-patenting and insufficiency. The patent claims swellable dosage forms that include a size element (the lengths of the axes of the formulation), a time element (the time required to swell to the claimed size) and a shape element (an oval or parallelogram). When these elements are combined, they increase gastric retention of the dosage form.

With respect to anticipation and double-patenting, the Court found that the prior art document on which Generic Partners relied for both allegations did not disclose all three of the size, shape and time elements of the claimed formulations. With respect to obviousness, the Court found that although the size and time elements may have been disclosed, neither the shape element nor the combination of all three elements had been. Given that it was not known that dosage shapes would affect gastric retention, it could not be obvious to use an oval shape. With respect to insufficiency, the Court accepted Valeant’s evidence that any experimentation required to optimize the claimed dosage forms would be routine, and found the lack of data and examples in the patent irrelevant to sufficiency. 

Generic Partners may appeal as of right.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Smart & Biggar | Attorney Advertising

Written by:

Smart & Biggar
Contact
more
less

Smart & Biggar on:

Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide
- hide

This website uses cookies to improve user experience, track anonymous site usage, store authorization tokens and permit sharing on social media networks. By continuing to browse this website you accept the use of cookies. Click here to read more about how we use cookies.